Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. medical centers, 2012 to 2014

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 7, 2016, Pages 4355-4360

  Sader, Helio S ^a   Castanheira, Mariana ^a   Flamm, Robert K ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; ANTIINFECTIVE AGENT; AVIBACTAM; AZABICYCLO DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MIC50; MIC90; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTION; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CEFTAZIDIME; ENTEROBACTERIACEAE; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTIONS;

EID: 84977137886     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00405-16     Document Type: Article

References (20)

1. Lane DR, Takhar SS. 2011. Diagnosis and management of urinary tract infection and pyelonephritis. Emerg Med Clin North Am 29:539-552. http://dx.doi.org/10.1016/j.emc.2011.04.001.
2. Briongos-Figuero LS, Gomez-Traveso T, Bachiller-Luque P, Dominguez-Gil Gonzalez M, Gomez-Nieto A, Palacios-Martin T, Gonzalez-Sagrado M, Duenas-Laita A, Perez-Castrillon JL. 2012. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract 66:891-896. http://dx.doi.org/10.1111/j.1742-1241.2012.02991.x.
3. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. 2013. Prevalence of β-lactamase encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 57:3012-3020. http://dx.doi.org/10.1128/AAC.02252-12.
4. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/s40265-013-0013-7.
5. Coleman K. 2011. Diazabicyclooctanes: a potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol 14:550-555. http://dx.doi.org/10.1016/j.mib.2011.07.026.
6. Bush K. 2015. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46:483-493. http://dx.doi.org/10.1016/j.ijantimicag.2015.08.011.
7. Avycaz. 2015. Avycaz prescribing information. http://www.avycaz.com. Forest Laboratories, New York, NY. Accessed 29 January 2016.
8. Clinical and Laboratory Standards Institute. 2016. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Tenth edition. M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
10. EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 6.0, January 2016. http://www.eucast.org/clinical-breakpoints/. Accessed January 2016.
11. Wyeth Pharmaceuticals. 2014.Tygacil® package insert. Wyeth Pharmaceuticals, Dallas, TX. http://www.tygacil.com. Accessed 25 January 2016.
12. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103-e120. http://dx.doi.org/10.1093/cid/ciq257.
13. Wagenlehner FM, Cek M, Naber KG, Kiyota H, Bjerklund-Johansen TE. 2012. Epidemiology, treatment and prevention of healthcare-associated urinary tract infections. World J Urol 30:59-67. http://dx.doi.org/10.1007/s00345-011-0757-1.
14. Koningstein M, van der Bij AK, de Kraker ME, Monen JC, Muilwijk J, de Greeff SC, Geerlings SE, van Hall MA, ISIS-AR Study Group. 2014. Recommendations for the empirical treatment of complicated urinary tract infections using surveillance data on antimicrobial resistance in the Netherlands. PLoS One 9:e86634. http://dx.doi.org/10.1371/journal.pone.0086634.
15. Sader HS, Flamm RK, Jones RN. 2014. Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011). J Chemother 26:133-138. http://dx.doi.org/10.1179/1973947813Y.0000000121.
16. Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez-Brocal A, Miranda-Casas C, Navarro-Mari JM, Gutierrez-Fernandez J. 2014. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control 42:1033-1038. http://dx.doi.org/10.1016/j.ajic.2014.06.013.
17. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 58:833-838. http://dx.doi.org/10.1128/AAC.01896-13.
18. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. 2015. Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains. Antimicrob Agents Chemother 59:3509-3517. http://dx.doi.org/10.1128/AAC.00163-15.
19. Lahiri SD, Walkup GK, Whiteaker JD, Palmer T, McCormack K, Tanudra MA, Nash TJ, Thresher J, Johnstone MR, Hajec L, Livchak S, McLaughlin RE, Alm RA. 2015. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother 70:1650-1658. http://dx.doi.org/10.1093/jac/dkv004.
20. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:5324-5330. http://dx.doi.org/10.1128/AAC.00678-15.